1. Home /
    2. Altai Protocol Library /
  2. New Indication: Encorafenib Plus Binimetinib in Patients with BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Encorafenib Plus Binimetinib in Patients with BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer

New Indication: Encorafenib Plus Binimetinib in Patients with BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer
Study:
  • Phase II, single-arm study (PHAROS)
  • Treatment-naïve and previously treated with BRAFV600E-mutant metastatic NSCLC
  • Encorafenib 450 daily + Bininmetinib 45 mg twice daily q28 day cycles (n=98)
Efficacy:
  • ORR: 75.0% [62%-85%] in treatment naïve and 46% [30%-63%) in previously treated group
  • mDOR: NR and 16.7 mos
  • mPFS: NR and 9.3 mos [6.2-NR]
Safety:
  • Any grade: nausea (%50), diarrhea (%43), fatigue (%32)
  • Grade≥3 AEs: ALT increased (5%), AST increased (7%), diarrhea (4%), anemia (3%).

Journal of Clin Oncol 2023 JUN 04

Riely J.G. et al. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer.

http://doi.org/10.1200/JCO.23.00774

Reviewed by Elvin CHALABİYEV, MD on JUN 10, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More